Merlion Pharms Gmbh patents expiration
1. Xtoro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119859 | MERLION PHARMS GMBH | Methods for treating otic infections |
Jul, 2030
(6 years from now) | |
| US9993483 | MERLION PHARMS GMBH | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(6 years from now) | |
| US8536167 | MERLION PHARMS GMBH | Methods for treating ophthalmic, otic, or nasal infections |
Aug, 2031
(7 years from now) | |
| US9504691 | MERLION PHARMS GMBH | Finafloxacin suspension compositions |
Nov, 2033
(10 years from now) | |
Drugs and Companies using FINAFLOXACIN ingredient
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
More Information on Dosage
XTORO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic